Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: Clinical and economic implications of a single-tablet formulation of diclofenac/misoprostol

American Journal of Managed Care

Volumn 4, Issue 5, 1998, Pages 687-697

  Goldstein, Jay L ^a   Larson, Leanne R ^b   Yamashita, Beverly D ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ClinTrials Ovation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTHROTEC; DICLOFENAC; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; KETOPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PROTON PUMP INHIBITOR; SULINDAC;

CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG MECHANISM; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE MANAGEMENT; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; STOMACH MUCOSA INJURY; TABLET FORMULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CANADA; COST OF ILLNESS; DICLOFENAC; DRUG COMBINATIONS; HUMANS; MISOPROSTOL; MODELS, ECONOMETRIC; RISK FACTORS; STOMACH DISEASES; UNITED STATES;

EID: 0031861079     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Gabriel SE, Fehring RA. Trends in the utilization of non-steroidal anti-inflammatory drugs in the United States 1866-1990. J Clin Epidemiol 1992;45:1041-1044.
2. Miller LG, Prichard JG. Current issues in NSAID therapy. Prim Care 1990;17:589-601.
3. Cummings DM, Amadio P Jr. A review of selected newer nonsteroidal anti-inflammatory drugs. Am Family Physician 1994;49:1197-1202.
4. Hirschowitz BI. Nonsteroidal anti-inflammatory drugs and the gut. Southern Med J 1996;89:259-263.
5. Agrawal NM, Van Kerckhove HEJM, Erhardt LJ, Geis GS. Misoprostol co-administered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. Dig Dis Sci 1995;40:1125-1131.
6. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995;141:539-545.
7. Hollander D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: Prophylactic and therapeutic strategies. Am J Med 1994;96:274-281.
8. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156:1530-1536.
9. Bjorkman DJ. Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury. Am J Med 1996;101(suppl 1A):25S-32S.
10. PDA's NSAID class labeling estimate of 4-6% GI adverse reaction annually is not valid. PMA maintains: PMA proposes industry-consensus NSAID label warning. F-D-C Reports, USFDA, November 30 1987;30:8-9.
11. Butt JH, Barthel JS, Moore RA. Clinical spectrum of the upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Am J Med 1988;84:5-14.
12. Fries J. Toward an understanding of NSAID-related adverse events: The contribution of longitudinal data. Scand J Rheumatol 1996;25(suppl 102):3-8.
13. Kendall BJ, Peura DA. NSAID-associated gastrointestinal damage and the elderly. Pract Gastroenterol 1993;17:13-29.
14. Fries JF. Assessing and understanding patient risk. Scand J Rheumatol 1992;(suppl)92:21-24.
15. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy. Arch Intern Med 1986;146:1075-1076.
16. Zeidler H. Epidemiology and economics of NSAID-induced gastropathy. Scand J Rheumatol 1992;(suppl)92:3-8.
17. Hawkey CJ. Nonsteroidal anti-inflammatory drugs and the gastric mucosa: Mechanisms of damage and protection. Aliment Pharmacol Ther 1988;2(suppl 1):57-64.
18. Champion GD, Feng PH, Azuma T, et al. NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus. Drugs 1997;53:6-19.
19. Cryer B, Feldman M. Treatment and prevention of NSAID-induced ulcers. Fed Pract 1995 December;22-38.
20. Scheiman JM. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 1996;25:279-298.
21. Estes LL, Fuhs DW, Heaton AH, Butwinick CS. Gastric ulcer perforation, associated with the use of injectable ketorolac. Pharmacotherapy 1993;27:42-43.
22. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 10:1078-1088.
23. Carson JL, Strom BL, Morse ML, et al. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med 1987;147:1054-1059.
24. Lanza FL, Royer GL Jr, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980;303:136-138.
25. Scheiman JM, Behler EM, Berardi RR, et al. Salicylsalicylic acid causes less gastroduodenal mucosal damage than enteric-coated aspirin: An endoscopic comparison. Dig Dis Sci 1989;34:229-232.
26. Vane JR, Mitchell JA, Appelton I, et al. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA 1994;91:2046-2050.
27. Bernsdorff KR, Agrawal RM, Brodmerkel GJ. Nonsteroidal anti-inflammatory drugs: Gastroduodenal injury and beyond. Dig Dis Sci 1995;13:251-266.
28. Laine L, Sloane R, Ferretti M, Cominelli F. A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc 1995;42:428-433.
29. Lipscomb CR, Wallis N, Armstrong G, et al. Gastric mucosal adaptation to etodolac and naproxen. Ailment Pharmacol Ther 1995;9:379-385.
30. Porro GB, Montrone F, Petrillo M, et al. Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. Am J Gastroenterol 1995;90:1485-1488.
31. Makarowski W, Weaver A, Rubin B, et al. The efficacy, tolerability and safety of 1200 mg/d of oxaproxin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee. Clin Ther 1996;18:114-124.
32. Roth SH, Bennett R, Caldron P, et al. A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. J Rheumatol 1994;21:1118-1123.
33. Lightfoot R. Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis. Etodolac study 326 rheumatoid arthritis investigators group. J Rheumatol 1997;(suppl 47):10-16.
34. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 115:787-796.
35. Pearson SP, Kelberman I. Gastrointestinal effects of NSAIDs: Difficulties in detection and management. Postgrad Med 1996;100:131-143.
36. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-1158.
37. Hawkey CJ, Langstrom G, Naesdal J, Yeomans ND. Significance of dyspeptic symptoms during healing and maintenance of NSAID-associated gastroduodenal lesions with omeprazole, misoprostol and ranitidine. Gastroenterology 1997;112:A144. Abstract.
38. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models. Am J Med 1991;91: 213-222.
39. Valentini M, Cannizzaro R, Poletti M, et al. Nonsteroidal anti-inflammatory durgs for cancer pain: Comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. J Clin Oncol 1995;13:2637-2642.
40. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Arthritis Rheum 1995;38:1535-1540.
41. Al MJ, Bowine MC, Rutten FFH. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis. Pharmacoeconomics 1996;10:141-151.
42. Sclar DA, Robinson LM, Maheu A, Skaer TL. Prescribing rationale and budgetary outcomes associated with the introduction of combined formulation of diclofenac sodium and misoprostol in Canada. J Intl Med Res 1995;23:439-448.
43. Singh G, Terry R, Ramey D, Triadafilopoulos G. Risk factors for serious NSAID-related complications:A prospective multivariate lifetable analysis. Gastroenterology 1997;112:A42. Abstract.
44. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996;334:1435-1439.
45. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre, double-blind, placebo-controlled trial. Lancet 1988; 2:1277-1280.
46. American College of Rheumatology AD HOC Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-722.
47. Tamblyn R, Berkson L, Dauphinee D, et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 1997;127:429-438.
48. Oddsson E, Gudjonsson H, Thjodleifsson JB. Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen. Scand J Gastroenterol 1992;27:1045-1048.
49. Ehsanullah RSB, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine. Br Med J 1988;297:1017-1021.
50. Robinson MG, Griffin JW, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989;34: 424-428.
51. Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997;112:1817-1822.
52. Oddsson E, Gudjonsson H, Thjodleifsson B. Protective effect of omeprazole or ranitidine against naproxen induced damage to the human gastroduodenal mucosa. Scand J Gastroenterol 1990;25:13.
53. Graham DY. High-dose famotidine for prevention of NSAID ulcers? Gastroenterology 1997;112:2143-2144.
54. Koch M, Dezi A, Ferrario F, Capurso L. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 1996;156:2321-2332.
55. Walan A, Bader J-P, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320:69-75.
56. Lauritsen K, Rutgersson K, Boiling E, et al. Omeprazole 20 or 40 mg daily for healing of duodenal ulcer? A double-blind comparative study. J Gastroenterol Hepatol 1992;4:995-1000.
57. Eriksson S, Longström G, Rikner L, et al. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: A meta-analysis. Eur J Gastroenterol Hepatol 1995;7:467-475.
58. Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for NSAID users. Gastroenterology 1996;110:A86. Abstract.
59. Hawkey CJ, Swannell AJ, Yeomans ND, et al. Site specific ulcer relapse in non-steroidal anti-inflammatory drug (NSAID) users: Improved prognosis with H. pylori and with omeprazole compared to misoprostol. Gut 1996;39(suppl 1):A149. Abstract.
60. Ekstrom P, Carling I, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic Multicentre Study. Scand J Gastroenterol 1996;31:753-758.
61. Mosby's Complete Drug Reference Physicians GenRx. 1997, St. Louis: Mosby-Year Book Inc.;1997:1450-1452.
62. Raskin JB, White RH, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: A prospective, double-blind, multicenter study. Am J Gastroenterol 1996;91:223-227.
63. Bianchi Porro G, Lazzaroni M, Petrillo M. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients. Am J Gastroenterol 1997;92:663-667.
64. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. Ann Intern Med 1991;115:195-200.
65. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241-249.
66. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: A comparison of three regimens. Ann Intern Med 1995;123:344-350.
67. De Melo Gomes JA. The safety of Arthrotec in patients with rheumatoid arthritis or osteoarthritis: An assessment of the upper gastrointestinal tract by endoscopy. Scand J Rheumatol 1992;(suppl 96);23-31.
68. Verdickt V, Moran C, Hantzschel H, et al. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scan J Rheumatol 1992;21:85-91.
69. Bocanegra TS, Ball J, Geis GS, Wallemark C. Fixed combinations of diclofenac/misoprostol in osteoarthritis. Rheumatol Eur 1996;25(suppl 1):46. Abstract.
70. Bocanegra TS, Weaver AL, Tindall EA, et al. Efficacy and gastrointestinal safety of diclofenac/misoprostol compared with diclofenac in osteoarthritis of the knee or hip: A randomized placebo controlled trial. J Rheumatol. In press.
71. Hatoum HT, Ware JE, Keller SD, et al. Effect of diclofenac and fixed combinations of diclofenac and misoprostol on health-related quality of life in patients with osteoarthritis. In: Program and Abstracts of the 19th Annual Meeting of the International League Against Rheumatism;1997:46.
72. De Pouvourville G. Evaluating the real cost of NSAID therapy; "shadow costs" relating to the treatment of gastrointestinal side effects. Br J Med Econ 1992;5:45-50.
73. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988;84(suppl 2A):20-24.
74. Knill-Jones R, Drummond M, Kohli H, Davies L. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J 1990;66:639-646.
75. De Pouvourville G. The iatrogenic cost of nonsteroidal anti-inflammatory drug therapy. Br J Rheumatol 1995; 34(suppl 1):19-24.
76. Elixhauser A, McCarthy E. Clinical Classifications for Health Policy Research, Version 2. Hospital inpatient statistics (AHCPR Publication No. 96-0017). Healthcare Cost and Utilization Project (HCUP-3) Research Note 1. Rockville, MD: Agency for Health Care Policy and Research;1996.
77. Pitcher JL. Therapeutic endoscopy and bleeding ulcers: Historical overview. Gastrointest Endosc 1990;36(suppl 5): 2-7.
78. Goldstein J, Larson L, Yamashita B, Boyd M. Management of NSAID-induced gastropathy: An economic decision analysis. Clin Ther 1997;19:1496-1509.
79. Gabriel SE, Campion ME, O'Fallon M. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994;37:333-341.